Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 4 2Phase 3 2Phase 1/2 2Phase 2 1

Status

Completed 19Unknown 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pigmentation Disorders 1Hemangioma, Capillary 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Imiquimod × Clear all
NCT00979550 2018-03-22

The Effects of Aldara as an Adjunct to Laser Treatment

University of Kentucky

Phase 2 Terminated
7 enrolled 4 charts

Pigmentation Disorders, Hemangioma, Capillary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡